# Jeff Elton

> Jeff Elton, Ph.D., is the founding CEO and now Vice Chairman of ConcertAI, a Cambridge-based company building generative and predictive AI on the world's largest multi-modal oncology dataset. He grew the company from a 2017 startup into a roughly $1.9 billion business with about 1,300 employees, acquiring TeraRecon's imaging technology and ASCO's CancerLinQ network along the way. A former Accenture managing director, Novartis research COO, and McKinsey partner, he co-authored the widely cited book Healthcare Disrupted and chairs the MassBio board.

- **Role:** Vice Chairman at ConcertAI
- **Organizations:** ConcertAI, MassBio, Accenture, Novartis Institutes for BioMedical Research, McKinsey & Company
- **Nationality:** American
- **Education:** Ph.D. in Business Economics, University of Chicago Booth School of Business, MBA, University of Chicago
- **Known for:** Founded and scaled ConcertAI to roughly 1,300 employees and a $1.9 billion valuation, Led acquisitions of TeraRecon's imaging AI and ASCO's CancerLinQ oncology network, Built what ConcertAI describes as the largest and most diverse multi-modal oncology dataset worldwide

## Career timeline

- **pre-2017** — Partner at McKinsey & Company
- **pre-2017** — Global Chief Operating Officer and SVP Strategy at Novartis Institutes for BioMedical Research
- **pre-2017** — Managing Director, Accenture Strategy/Patient Health; North America Life Sciences Strategy Lead and Global Managing Director of Predictive Health Intelligence
- **2016** — Co-authored Healthcare Disrupted (Wiley) with Anne O'Riordan
- **2017** — Founded ConcertAI as founding CEO
- **2022** — Raised $150M Series C from Sixth Street at a $1.9B valuation
- **2024** — Launched generative and predictive AI solutions including CARA AI at ASCO
- **2025** — Transitioned from CEO to Vice Chairman of ConcertAI; Eron Kelly named CEO

## Achievements

- Founded and scaled ConcertAI to roughly 1,300 employees and a $1.9 billion valuation
- Led acquisitions of TeraRecon's imaging AI and ASCO's CancerLinQ oncology network
- Built what ConcertAI describes as the largest and most diverse multi-modal oncology dataset worldwide
- Raised $150 million Series C from Sixth Street in 2022
- Co-authored the widely cited Healthcare Disrupted (Wiley, 2016)
- Chairs the board of MassBio, the Massachusetts Biotechnology Council

## Latest updates

- **2025-05** — Transitioned from CEO to Vice Chairman of ConcertAI as Eron Kelly was appointed CEO.
- **2024-06** — Introduced predictive and generative AI solutions including CARA AI at the ASCO Annual Meeting.

## Links

- Website: https://concertai.com
- LinkedIn: http://www.linkedin.com/in/jelton

---

Profile page: https://yespress.io/jeff-elton
Published by YesPress — https://yespress.io
Last updated: 2026-06-11